Patents Assigned to Ocuphire Pharma, Inc.
  • Aqueous ophthalmic solutions of phentolamine and medical uses thereof
    Patent number: 11844858
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: December 19, 2023
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan R. Meyer
  • Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
    Patent number: 11717510
    Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: August 8, 2023
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer
  • Highly pure phentolamine mesylate and methods for making same
    Patent number: 11566005
    Abstract: This invention provides methods for synthesizing phentolamine mesylate from phentolamine and methanesulfonic acid in the presence of acetone and water. The methods of the present invention provide highly pure phentolamine mesylate. The invention also provides highly pure phentolamine mesylate.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: January 31, 2023
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Daniela Carmen Oniciu
  • Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
    Patent number: 11400077
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: August 2, 2022
    Assignee: Ocuphire Pharma, Inc.
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • Aqueous ophthalmic solutions of phentolamine and medical uses thereof
    Patent number: 11090261
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: August 17, 2021
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer
  • Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
    Patent number: 11000509
    Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: May 11, 2021
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer
  • Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
    Patent number: 10993932
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: May 4, 2021
    Assignee: Ocuphire Pharma, Inc.
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • Aqueous ophthalmic solutions of phentolamine and medical uses thereof
    Patent number: 10772829
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 15, 2020
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer
  • Aqueous ophthalmic solutions of phentolamine and medical uses thereof
    Patent number: 10278918
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: May 7, 2019
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer